Shail Modi, Senior Scientist at Stramsen Biotech, Inc, shared a commentary about his research article:
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with limited treatment options, largely due to the absence of well-defined targeted therapies. In this study, we integrated computational biology with experimental validation to identify novel regulatory drivers of TNBC. Using multiple transcriptional regulatory network approaches, we identified a robust set of master regulators-key upstream factors that control the expression of numerous downstream genes and play critical roles in tumor biology.
This study not only provides a comprehensive list of these master regulators and their associated targets but also strengthens confidence in their relevance by leveraging three independent network inference methods. Importantly, we experimentally validated a novel regulatory relationship between NFE2L3 (NRF3) and BHLHE40, uncovering a previously unrecognized mechanism contributing to TNBC pathophysiology.
Overall, this work highlights the strength of combining computational systems biology with wet-lab validation to uncover clinically relevant molecular mechanisms. The identified NFE2L3–BHLHE40 axis represents a promising direction for future biomarker discovery and targeted therapeutic development in TNBC, a disease in urgent need of new treatment strategies.
Thank you to Massachusetts College of Pharmacy and Health Sciences (MCPHS University) for their support, and to The Oncology Research Journal by Tech Science Press for publishing the article.
Title: BHLHE40 Is a Transcriptional Regulatory Target of NFE2L3 in Triple-Negative Breast Cancer
Authors: Shail Rakesh Modi, Terrick Andey, George Acquaah-Mensah
Read the Full Article.
